Innovative strategies in genitourinary cancer: the role of oncolytic viruses DOI Creative Commons
Jie Zhang,

Kepu Liu,

Zhu Zheng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 11, 2024

Urinary tumors pose a significant health threat because of their high prevalence and recurrence rates. Despite the availability various treatment options, many patients poorly respond to traditional therapies, highlighting urgent need for alternative approaches. Oncolytic viruses are promising therapeutic agents. These exploit unique characteristics cancer cells specifically target destroy them, thereby triggering potent antitumor immune responses. This review delves into recent advancements future prospects oncolytic viruses, focusing on application in renal, bladder, prostate cancers. By discussing practical implications potential different including cowpox virus, adenovirus, measles coxsackievirus, reovirus, we pave way further exploration refinement this exciting field.

Language: Английский

Advances in preclinical and clinical studies of oncolytic virus combination therapy DOI Creative Commons
Wenlong Du,

Jintong Na,

Liping Zhong

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 7, 2025

Oncolytic viruses represent a distinct class of that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic encounter several challenges as standalone therapies. Consequently, the combination with other therapeutic modalities has emerged prominent research focus. This paper summarizes tumor-killing mechanisms viruses, explores integration radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, CAR-NK therapies, provides an overview related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for translation virus

Language: Английский

Citations

1
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges DOI Open Access
S. A. Tilakaratne Bandara, Sreejith Raveendran

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 821 - 821

Published: Feb. 27, 2025

Cancer remains a leading global health challenge, placing immense burdens on individuals and healthcare systems. Despite advancements in traditional treatments, significant limitations persist, including treatment resistance, severe side effects, disease recurrence. Immunotherapy has emerged as promising alternative, leveraging the immune system to target eliminate tumour cells. However, challenges such immunotherapy patient response variability, need for improved biomarkers limit its widespread success. This review provides comprehensive analysis of current landscape cancer immunotherapy, highlighting both FDA-approved therapies novel approaches clinical development. It explores checkpoint inhibitors, cell gene therapies, monoclonal antibodies, nanotechnology-driven strategies, offering insights into their mechanisms, efficacy, limitations. By integrating emerging research advancements, this underscores continued innovation optimise overcome existing barriers.

Language: Английский

Citations

1
ROS Induced by Aphrocallistes vastus Lectin Enhance Oncolytic Vaccinia Virus Replication and Induce Apoptosis in Hepatocellular Carcinoma Cells DOI Creative Commons
Yanan Zhang, Ying Zhu,

Gaohui Jiang

et al.

Marine Drugs, Journal Year: 2024, Volume and Issue: 22(7), P. 307 - 307

Published: June 30, 2024

Oncolytic virotherapy is expected to provide a new treatment strategy for cancer. Aphrocallistes vastus lectin (AVL) Ca2+-dependent receptor containing the conserved domain of C-type and hydrophobic N-terminal region, which can bind bird’s nest glycoprotein D-galactose. Our previous studies suggested that oncolytic vaccinia virus (oncoVV) armed with AVL gene exerted remarkable replication antitumor effects in vitro vivo. In this study, we found oncoVV-AVL may reprogram metabolism hepatocellular carcinoma cells promote ROS, elevated ROS subsequently promoted viral induced apoptosis. This study will theoretical basis application liver

Language: Английский

Citations

4
An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application DOI Creative Commons
Dan Su,

Han Li-ping,

Chengyu Shi

et al.

Virulence, Journal Year: 2024, Volume and Issue: 15(1)

Published: Nov. 7, 2024

Herpes simplex virus type 1 (HSV-1) is a globally widespread that causes and associates with wide range of diseases, including herpes encephalitis, keratitis, labialis. The interaction between HSV-1 the host involves complex immune response mechanisms, recognition viral invasion, maintenance latent infection, triggering reactivation. Antiviral therapy core treatment for infections. Meanwhile, vaccine development employs different strategies methods, several promising types have emerged, such as live attenuated, protein subunit, nucleic acid vaccines, offering new possibilities prevention infection. Moreover, can be modified into therapeutic vector gene tumour immunotherapy. This review provides an in-depth summary infection-associated innate adaptive responses, disease pathogenesis, current approaches, recent advances in development, applications cancer treatment. Through systematic multiple aspects HSV-1, this study aims to provide comprehensive detailed reference public on prevention, control, HSV-1.

Language: Английский

Citations

4
Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction DOI Creative Commons

Yufu Zhu,

Xuefeng Zhang, Jiaqi Jin

et al.

Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)

Published: Feb. 15, 2025

Abstract Background Glioblastoma is a highly aggressive and devastating primary brain tumor that resistant to conventional therapies. Oncolytic viruses represent promising therapeutic approach for glioblastoma by selectively lysing cells eliciting an anti-tumor immune response. However, the clinical efficacy of oncolytic often hindered challenges such as short persistence, host antiviral responses, T cell dysfunction. Methods We have developed novel strategy “dressing” with anti-PD-1 antibodies alendronate (PD-1/Al@OV) prevent premature clearance enhance function, thereby improving immunotherapy outcomes against glioma. Results found in high reactive oxygen species environment tumor, PD-1/Al@OV disassembled release viruses, anti-PD-1, alendronate. The released blocked PD-1/PD-L1 pathway, activating cells; eliminated tumor-associated macrophages, increasing concentration viruses; directly lysed cancer cells, enhancing intratumoral infiltration. Conclusion This effectively improved immunosuppressive microenvironment achieved robust effect. Consequently, this study presents combination therapy improvement microenvironment, offering new prospects application viruses.

Language: Английский

Citations

0
Recent advances in oncolytic virus combined immunotherapy in tumor treatment DOI Creative Commons
Xiaoli Zhou, Shunfeng Hu, Xin Wang

et al.

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101599 - 101599

Published: March 1, 2025

Language: Английский

Citations

0
Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies DOI Open Access

Valencia Mc Neil,

Seung Won Lee

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1408 - 1408

Published: April 23, 2025

A groundbreaking milestone in oncology has been the recognition and targeted elimination of malignant cells through cancer immunotherapy, which harnesses body’s immune system to attack [...]

Language: Английский

Citations

0
Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. DOI
Jin Guo, S. Xiong, Xinyuan Zhang

et al.

PubMed, Journal Year: 2025, Volume and Issue: 18(4)

Published: March 31, 2025

Background: While Bacillus Calmette-Guérin (BCG) remains the first-line therapy for high-risk bladder cancer, 30-40% of patients develop treatment resistance necessitating radical cystectomy, some are not suitable candidates this procedure. This underscores critical need novel therapeutic approaches. Emerging clinical evidence has increasingly supported potential oncolytic viruses in cancer treatment. Based on foundation, we investigated anti-tumor effects KD01, a type 5 recombinant adenovirus previously developed by our team engineered to express truncated BID (tBID), cancer. Methods: The cytotoxic and efficacy KD01 were systematically evaluated across human cell lines, death pathways RNA sequencing validated. Combination studies with cisplatin employed testing. In final stage, safety instillation was evaluated. Results: induced through multiple mechanisms, including oncolysis, immunogenic death, mitochondrial apoptosis. At higher doses, combined synergistically inhibited proliferation Additionally, amplified damage-associated molecular patterns (DAMPs) release immune activation; combination further enhanced process. Safety evaluations showed favorable tolerance intravesical perfusion KD01. Conclusions: dual action directly killing tumor cells activating immunity its as agent. These findings highlight preclinical informing design trials.

Language: Английский

Citations

0
Immunogenic cell death-based oncolytic virus therapy: a sharp sword of tumor immunotherapy DOI Creative Commons

Jingyu Zhang,

Jiahe Chen, Kezhi Lin

et al.

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 981, P. 176913 - 176913

Published: Aug. 16, 2024

Language: Английский

Citations

3
An in silico approach uncovering the competency of oncolytic human adenovirus 52 for targeted breast cancer virotherapy DOI Creative Commons
Muhammad Naveed,

Zainab Batool,

Tariq Aziz

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Nov. 2, 2024

Breast cancer remains a major health threat throughout the world specifically in women above 30 years of age however, it is rarely known to affect men as well. It characterized by abnormal division cells breast tissue resulting development malignancies. Various risk factors contributing include age, family history, genetic mutations (chiefly BRCA1 and BRCA2 genes) along with hormonal imbalances (oestrogen, progesterone, HER2). Early detection which can be obtained through frequent rounds self-examination, mammographic scanning, clinical assessment plays crucial role prevention disease. In addition, appropriate diagnosis assists better therapeutic responses. This study highlights considerable risks associated conventional treatment procedures arise increased demand advanced, secure, risk-free alternatives. Oncolytic viruses are potentially apparent for aim improving therapeutics reduced side effects. These act fundamental agent themselves that selectively target kill malignant without harm healthy tissues. The key objective research provide evidence Human Adenovirus 52 potent oncolytic virus highlight its capacity eliminate precision while causing least amount Validating in-silico method entails evaluating dependability computational modelling contrasting predictions findings from experiments rank secondary objective. workflow this utilized drug designing approaches including retrieval tertiary structures both Cancer Type 1 Susceptibility Protein (BRCA1) viral protein, their validation generating Ramachandran Plots determining favoured amino acid residue angles prediction active residues. Furthermore, focused on molecular dynamics docking proteins, interpretation interactions between docked complex, well dynamic simulations (MD) addition MMGBSA binding energy calculations. A successful protein provided significant score 329.2 +/- 24.3, furthermore, MD showed high RMSD peak at 2.8 Å, RMSF were maximum 3.5 Å highest protein-protein interaction, radius gyration was stable simulation representing elastic stability interaction value - 7882 kCal/mol. Moreover, calculation results notable release free 68.96 kCal/mol demonstrating effective bond formation complex. propose effectiveness treat cancer. selected potential candidate specific virotherapy. computer-aided discovery presents targeting would assist reagents therapy.

Language: Английский

Citations

2